Claudia Druschel1, Klaus-Dieter Schaser, Jan M Schwab. 1. Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), CHARITÉ Campus Mitte-University Medicine Berlin, Germany.
Abstract
STUDY DESIGN: Written mail-out survey. OBJECTIVE: To determine current practice in high-dose methylprednisolone succinate (MPSS) administration for treatment of acute spinal cord injury (SCI) in Germany. SUMMARY OF BACKGROUND DATA: Reanalysis of the National Acute Spinal Cord Injury Studies (NASCIS) resulted in criticism of the use of high-dose MPSS for treatment of acute SCI. Subsequently, SCI treatment guidelines were revised leading to a reduction in MPSS use across North America. The impact of these revisions on SCI treatment in Germany is not known. METHODS: A questionnaire was sent to all trauma, orthopedic and neurosurgical departments of German university centers, affiliated teaching hospitals, and specialized SCI care centers. Survey included 6 questions about the administration of MPSS after acute SCI. RESULTS: Three hundred seventy-two respondents completed the survey (response rate: 51% overall, 76% university hospitals, 85% specialized SCI care centers). Overall, 55% of departments that treat SCI prescribe MPSS. Among them, 73% are "frequent" users administering MPSS to more than 50% of their patients. Ten percent prescribe according to NASCIS I, 43% NASCIS II, 33% NASCIS III, and 13% "generic protocols." As justification for MPSS treatment, "effectiveness" ranked before "common practice" and "medicolegal reasons." "Specialized" SCI care centers differ in that (1) MPSS is administered less frequently, (2) NASCIS I doses are not used, and (3) during the past several years, practice patterns are more likely to have shifted away from the treatment of SCI with MPSS. CONCLUSION: About one-half of the institutions continue to prescribe MPSS in the setting of acute SCI. A need for further education in almost one-fourth of German departments treating acute SCI is demonstrated through responses indicating use of the outdated NASCIS I protocol, a "legal need" or "unchanged MPSS application during the last years." "Specialized" SCI centers are more likely to change their practice in accordance with evolving literature. LEVEL OF EVIDENCE: 3.
STUDY DESIGN: Written mail-out survey. OBJECTIVE: To determine current practice in high-dose methylprednisolone succinate (MPSS) administration for treatment of acute spinal cord injury (SCI) in Germany. SUMMARY OF BACKGROUND DATA: Reanalysis of the National Acute Spinal Cord Injury Studies (NASCIS) resulted in criticism of the use of high-dose MPSS for treatment of acute SCI. Subsequently, SCI treatment guidelines were revised leading to a reduction in MPSS use across North America. The impact of these revisions on SCI treatment in Germany is not known. METHODS: A questionnaire was sent to all trauma, orthopedic and neurosurgical departments of German university centers, affiliated teaching hospitals, and specialized SCI care centers. Survey included 6 questions about the administration of MPSS after acute SCI. RESULTS: Three hundred seventy-two respondents completed the survey (response rate: 51% overall, 76% university hospitals, 85% specialized SCI care centers). Overall, 55% of departments that treat SCI prescribe MPSS. Among them, 73% are "frequent" users administering MPSS to more than 50% of their patients. Ten percent prescribe according to NASCIS I, 43% NASCIS II, 33% NASCIS III, and 13% "generic protocols." As justification for MPSS treatment, "effectiveness" ranked before "common practice" and "medicolegal reasons." "Specialized" SCI care centers differ in that (1) MPSS is administered less frequently, (2) NASCIS I doses are not used, and (3) during the past several years, practice patterns are more likely to have shifted away from the treatment of SCI with MPSS. CONCLUSION: About one-half of the institutions continue to prescribe MPSS in the setting of acute SCI. A need for further education in almost one-fourth of German departments treating acute SCI is demonstrated through responses indicating use of the outdated NASCIS I protocol, a "legal need" or "unchanged MPSS application during the last years." "Specialized" SCI centers are more likely to change their practice in accordance with evolving literature. LEVEL OF EVIDENCE: 3.
Authors: Pinar Yalinay Dikmen; Matthew F Halsey; Altug Yucekul; Marinus de Kleuver; Lloyd Hey; Peter O Newton; Irem Havlucu; Tais Zulemyan; Caglar Yilgor; Ahmet Alanay Journal: Spine Deform Date: 2020-11-23
Authors: Han Ding; Ang Li; Chao Sun; Jianping Zhang; Jun Shang; Haoshuai Tang; Junjin Li; Min Wang; Xiaohong Kong; Zhijian Wei; Shiqing Feng Journal: Ann Transl Med Date: 2022-09
Authors: Nathan Evaniew; Vanessa K Noonan; Nader Fallah; Brian K Kwon; Carly S Rivers; Henry Ahn; Christopher S Bailey; Sean D Christie; Daryl R Fourney; R John Hurlbert; A G Linassi; Michael G Fehlings; Marcel F Dvorak Journal: J Neurotrauma Date: 2015-07-17 Impact factor: 5.269
Authors: Asdrubal Falavigna; Francine W Quadros; Alisson R Teles; Chung Chek Wong; Giuseppe Barbagallo; Darrel Brodke; Abdulaziz Al-Mutair; K Daniel Riew Journal: Global Spine J Date: 2018-02-11